公开(公告)号：EP3403661A1

公开(公告)日：2018-11-21

申请号：EP17738490.6

申请日：2017-01-12

申请人： Waseda University ,  Kabushiki Kaisha Yakult Honsha

发明人： NAKAO, Yoichi ,  ASANO, Shigetaka ,  ARAI, Daisuke ,  KASE, Yukari ,  SHIMOMOTO, Teppei

IPC分类号： A61K35/655 ,  A61K31/215 ,  A61K45/00 ,  A61P35/00 ,  A61P43/00 ,  C07C67/56 ,  C07C69/145

CPC分类号： A61K31/215 ,  A61K35/655 ,  A61K45/00 ,  C07C67/56 ,  C07C69/145

摘要： Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells. The present invention provides a pharmaceutical composition having inhibitory or suppressive activity against the niche formation of leukemic stem cells, a prophylactic agent against the recurrence of malignant tumor, which involves the combined use of other antitumor drugs, and the like.

公开(公告)号：EP2919813B1

公开(公告)日：2018-10-24

申请号：EP13854201.4

申请日：2013-11-12

申请人： F. Hoffmann-La Roche AG

发明人： XU, Min ,  BALAZS, Mercedesz ,  CHAI, Ning ,  CHIANG, Nancy ,  CHIU, Henry ,  JIN, Zhaoyu ,  LIN, Zhonghua ,  LUPARDUS, Patrick, J. ,  NAKAMURA, Gerald, R. ,  PARK, Hyunjoo ,  SWEM, Lee, R.

IPC分类号： A61K39/42 ,  C07K16/10 ,  A61P31/16

CPC分类号： C07K16/1018 ,  A61K31/215 ,  A61K31/235 ,  A61K31/24 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/94 ,  A61K2300/00

摘要： The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

公开(公告)号：EP3237393B1

公开(公告)日：2018-09-26

申请号：EP15817875.6

申请日：2015-12-24

申请人： Melchior Material And Life Science France

发明人： GUERRET, Olivier ,  GUILLONNEAU, Loic ,  DUFOUR, Samuel

IPC分类号： C07D317/22 ,  A61K31/341 ,  A61P25/00

CPC分类号： C07D317/22 ,  A61K9/007 ,  A61K31/19 ,  A61K31/215 ,  A61K31/341 ,  A61K47/06

公开(公告)号：EP3368086A1

公开(公告)日：2018-09-05

申请号：EP16860858.6

申请日：2016-10-28

申请人： Dermalink Technologies, Inc.

发明人： SAMBASIVAM, Mahesh

IPC分类号： A61K47/38 ,  A61K47/10

CPC分类号： A61K31/215 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10 ,  A61K47/183 ,  A61K47/38 ,  A61P17/02 ,  A61P31/04 ,  A61P31/12

摘要： The present disclosure relates to skin adhesives, antimicrobial compositions, and articles thereof, including methods and processes of forming such antimicrobial compositions, medical devices, and articles thereof. The antimicrobial compositions include, for example, adhesive compositions, gels, cleansers, wound dressings and foams.

公开(公告)号：EP1987825B1

公开(公告)日：2018-09-05

申请号：EP07714584.5

申请日：2007-02-20

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA ,  F. Hoffmann-La Roche AG

发明人： KUBOTA, Ryuji ,  OHTA, Tomoaki ,  HIRAYAMA, Tomoaki ,  MAEDA, Hiroyuki ,  VOLLAND, Christian ,  KAESTLE, Hans-Guenter

IPC分类号： A61K31/215 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  A61K47/04 ,  A61K47/10 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46 ,  A61P11/00 ,  A61P31/16

CPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/1623 ,  A61K31/215

摘要： The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25°C and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.

公开(公告)号：EP3221284A4

公开(公告)日：2018-08-01

申请号：EP15860844

申请日：2015-11-18

申请人： UNIV MARYLAND

发明人： NJAR VINCENT ,  MBATIA HANNAH ,  RAMAMURTHY VIDYA ,  RAMALINGAM SENTHILMURUGAN

IPC分类号： C07C13/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/167 ,  A61K31/4164 ,  A61P35/00

CPC分类号： A61K31/165 ,  A61K31/203 ,  A61K31/215 ,  A61K31/4164 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/505 ,  A61P35/00 ,  C07C403/20 ,  C07C2601/16 ,  C07D213/56 ,  C07D233/56 ,  C07D239/26

摘要： The synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling are discussed. In both breast and prostate cancer cell lines, these compounds induce Mnk1/2 degradation to substantially suppress eIF4E phosphorylation. In prostate cancer cells, the compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to inhibit AR transcriptional activity. The consequences of these multiple activities resulted in inhibition of cell growth and migration and induction of apoptosis. Finally and importantly, the compounds demonstrate strong in vitro and in vivo anti-breast and anti-prostate cancer activities, with no apparent host toxicities.

公开(公告)号：EP3169156B1

公开(公告)日：2018-07-25

申请号：EP15738721.8

申请日：2015-06-17

申请人： Fondation Méditerranée Infection ,  Université d'Aix-Marseille

发明人： RAOULT, Didier ,  ROLAIN, Jean-Marc ,  SANGARE, Abdoul Karim

IPC分类号： A61K31/7048 ,  A61K31/7052 ,  A61K31/215 ,  A61K31/496 ,  A61K31/65 ,  A61K45/06 ,  A01N37/44 ,  A01N43/90 ,  A61P31/00 ,  A61P33/14

CPC分类号： A61K31/65 ,  A01N37/44 ,  A01N43/90 ,  A61K31/215 ,  A61K31/496 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00 ,  A01N2300/00

公开(公告)号：EP3295936A1

公开(公告)日：2018-03-21

申请号：EP17170304.4

申请日：2010-01-08

申请人： Forward Pharma A/S

发明人： NILSSON, Henrik ,  RUPP, Roland

IPC分类号： A61K9/28 ,  A61K31/215 ,  A61P17/06 ,  A61K9/20 ,  A61K31/225

CPC分类号： A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

摘要： A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

摘要翻译： 包含侵蚀基质的药物制剂，所述侵蚀基质包含一种或多种富马酸酯以及一种或多种速率控制剂，其中所述侵蚀基质的侵蚀允许所述富马酸酯的受控释放。

公开(公告)号：EP2668212B1

公开(公告)日：2018-03-21

申请号：EP12701742.4

申请日：2012-01-27

申请人： Sanofi Biotechnology

发明人： HANOTIN, Corinne ,  BESSAC, Laurence ,  CHAUDHARI, Umesh

IPC分类号： C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61J1/05 ,  A61K31/215 ,  A61K31/366 ,  A61K31/404 ,  A61K31/435 ,  A61K31/47 ,  A61K31/505 ,  A61K31/395 ,  C07K14/47

CPC分类号： A61J1/05 ,  A61K31/215 ,  A61K31/366 ,  A61K31/404 ,  A61K31/435 ,  A61K31/47 ,  A61K31/505 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/4703 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/76

摘要： The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.

公开(公告)号：EP3280398A1

公开(公告)日：2018-02-14

申请号：EP16777388.6

申请日：2016-04-08

申请人： Bioresponse LLC

发明人： ZELIGS, Michael, A. ,  JACOBS, Irwin, C.

IPC分类号： A61K9/08 ,  A61K9/10 ,  A61K31/404 ,  A61K47/00 ,  A61K47/06

CPC分类号： A61K31/404 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K9/14 ,  A61K9/48 ,  A61K31/122 ,  A61K31/138 ,  A61K31/215 ,  A61K31/23 ,  A61K31/275 ,  A61K31/357 ,  A61K31/4045 ,  A61K31/59 ,  A61K45/06 ,  A61K47/00 ,  A61K47/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/24 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/46 ,  Y02A50/411 ,  A61K2300/00

摘要： Disclosed herein are self-emulsifying compositions and formulations of Diindolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.